Newsfeeds - Spark Newswire

2 minute read

Halozyme Sees FY22 Revenue $530M-$560M Vs $442.23M Est; Sees Adj. EPS $2.05-$2.20 Vs $1.85 Est

Today, 5:56 PM

2022 Financial Guidance: Revenue For 2022, Halozyme expects total revenue of $530 million to $560 million, representing growth of 23-26% over 2021 expected total revenue. The Company

HALO

2 minute read

12 Health Care Stocks Moving In Friday’s Intraday Session

By Benzinga Insights

Today, 5:56 PM

BFRI

4 minute read

The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares

By Shanthi Rexaline

Today, 5:56 PM

Here's a roundup of top developments in the biotech space over the last 24 hours.

ABBV

1 minute read

Janssen’s Subcutaneous Darzalex Combo Wins FDA Approval For Pretreated Multiple Myeloma

By Vandana Singh

Today, 5:56 PM

Johnson & Johnson's (NYSE: JNJ) Janssen Biotech Inc has

AMGN

1 minute read

Halozyme’s Q3 Sales Boosted By Darzalex; Lifts FY21 Earnings Outlook

By Vandana Singh

Today, 5:56 PM

Halozyme Therapeutics Inc (NASDAQ:HALO) reported Q3 revenue of $115.8 million compared to $65.3 million a year ago, beating the consensus of…

HALO

1 minute read

UPDATE: Halozyme Therapeutics Q3 Adj. EPS $0.55 Beats $0.42 Estimate, Sales $115.83M Beat $101.94M Estimate

By Benzinga Newsdesk

Today, 5:56 PM

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $0.55 per share which beat the analyst consensus estimate of $0.42 by 30.95 percent. This is a 77.42 percent increase over earnings of $0.31 per share

HALO

1 minute read

Halozyme Therapeutics Q3 EPS $1.48 Up From $0.25 YoY, Sales $115.83M Beat $101.94M Estimate

By Benzinga Newsdesk

Today, 5:56 PM

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $1.48 per share. This is a 492 percent increase over earnings of $0.25 per share from the same period last year. The company reported quarterly sales of

HALO

4 minute read

The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US

By Shanthi Rexaline

Today, 5:56 PM

Here's a roundup of top developments in the biotech space over the last 24 hours:

AADI

19 minute read

Earnings Scheduled For November 2, 2021

By Benzinga Insights

Today, 5:56 PM

Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion.

7 minute read

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline

By Shanthi Rexaline

Today, 5:56 PM

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.

ADPT